KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial. PMID 41794436 · Lancet · 2026-Mar-07 The trial is a Phase 3 randomized trial in oncology (breast cancer) with a time-to-event primary endpoint (arm lymphoedema reported as HR), but the intervention is radiotherapy (radiation dose fractionation), not a drug. The criteria require a drug-containing intervention for eligibility.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care. PMID 41793559 · Breast Cancer Res Treat · 2026-Mar-07 The study is an observational comparative effectiveness analysis using a target trial emulation framework on real-world data, not a report of an original Phase III/IIIb or Phase II/III randomized controlled trial with a drug intervention. It does not meet the criteria for a primary or secondary report of a definitive randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prophylactic para-aortic irradiation vs pelvic radiotherapy in pelvic node-positive carcinoma cervix in the setting of concurrent chemoradiation: a phase II open-label multi centric randomized controlled trial (PRO-PARA). PMID 41792812 · Trials · 2026-Mar-07 The record describes a protocol for a Phase II/III randomized trial in cervical cancer with a drug (cisplatin) intervention. While it meets many inclusion criteria (oncology, human, randomized, phase 3, drug intervention), it is excluded because it is a protocol without reported results, and no time-to-event efficacy endpoint (e.g., OS, PFS) or survival analysis (Kaplan-Meier, HR) is described. The primary endpoint mentioned is 'demonstration of reduction in the risk of para-aortic recurrence,' but the abstract does not report any data, results, or confirm it as a time-to-event outcome suitable for KM digitization.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya. PMID 41564838 · Vaccine · 2026-Mar-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate vaccine in Chinese children aged 2-5 years: A phase III study. PMID 41554243 · Vaccine · 2026-Mar-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6-23 months: phase III study (US/Puerto Rico). PMID 41792337 · Pediatr Res · 2026-Mar-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Suzetrigine (a NaV1.8 inhibitor) versus placebo for acute postoperative pain: A systematic review and meta-analysis of randomized controlled trials. PMID 41790692 · Medicine (Baltimore) · 2026-Mar-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). PMID 41786624 · Mod Rheumatol · 2026-Mar-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Kidney-Tonifying, Phlegm-Resolving, and Blood Stasis-Removing Therapy for Multiple Myeloma: Protocol for a Randomized Controlled Trial on Epigenetic and Immune Modulation. PMID 41813432 · JMIR Res Protoc · 2026-Mar-05 This is a protocol for a randomized trial in multiple myeloma, but it is not Phase III/IIIb or Phase II/III, and it lacks primary or secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Thermal ablation versus hepatectomy for solitary colorectal liver metastases up to 5 cm: a multicenter target trial emulation on safety, efficacy, and cost-effectiveness. PMID 41787469 · BMC Med · 2026-Mar-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat's Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia. PMID 41785204 · Am J Nephrol · 2026-Mar-05 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety of extending dosing intervals of denosumab in adults with solid cancer and bone metastasis: a review. PMID 41785076 · Br J Nurs · 2026-Mar-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
AI-Driven Analysis of Cardiopulmonary Exercise Tests to Identify Gas Exchange and Ventilatory Thresholds. PMID 41784915 · Sports Med · 2026-Mar-05 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical evaluation of the efficacy and safety of nasturtium herb and horseradish root versus placebo in the continuous prophylaxis of recurrent uncomplicated cystitis: a double-blind randomised clinical trial. PMID 41782129 · BMC Complement Med Ther · 2026-Mar-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Finerenone in Type 1 Diabetes and Chronic Kidney Disease. PMID 41780000 · N Engl J Med · 2026-Mar-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial). PMID 40884070 · Eur Heart J · 2026-Mar-05 The trial is a randomized, double-blind, placebo-controlled study in advanced cancer patients, but the primary endpoint is a composite of functional/well-being measures, not a time-to-event efficacy endpoint. Mortality is mentioned as a secondary safety measure, not as a primary or key secondary time-to-event endpoint for efficacy analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial. PMID 41782416 · Eur J Endocrinol · 2026-Mar-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Can topical coconut oil reduce late-onset sepsis in extremely preterm infants? A pragmatic cluster-randomised controlled trial protocol. PMID 41781050 · BMJ Open · 2026-Mar-04 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer. PMID 41781018 · J Immunother Cancer · 2026-Mar-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Lepodisiran: An Updated Review on a Novel and Emerging Lipoprotein (a) Lowering Agent. PMID 41779052 · Cardiol Rev · 2026-Mar-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical effectiveness of transversus abdominis plane block versus local anaesthesia wound infiltration for postoperative pain relief after laparoscopic appendicectomy in children: A multicentre, double-blind, randomised, controlled phase III trial. PMID 41777031 · Eur J Anaesthesiol · 2026-Mar-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Once-weekly somapacitan in children with Noonan syndrome: randomized controlled phase 3 trial. PMID 41774755 · Eur J Endocrinol · 2026-Mar-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. PMID 41586496 · Antimicrob Agents Chemother · 2026-Mar-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. PMID 41832961 · JNCI Cancer Spectr · 2026-Mar-03 The record describes a randomized trial with drug intervention and time-to-event endpoints. However, the formal trial phase (Phase III, IIIb, or II/III) is not explicitly stated in the provided metadata (title, abstract, publication types, or MeSH). The deterministic review also flagged 'phase3_evidence_unclear'. Without explicit phase information, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study. PMID 41774854 · Blood Adv · 2026-Mar-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Systematic Review Comparing Sex-Specific Outcomes of Prospective Clinical Trials and Subsequent Real-World Data Focusing on Systemic Treatment Options for Renal Cell Cancer. PMID 41774617 · Urol Int · 2026-Mar-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Potential bias in the clinical trial registration of patients with peripheral small-sized non-small cell lung cancer: Real-world data in the era of segmentectomy. PMID 41774196 · Surg Today · 2026-Mar-03 The record describes an observational study analyzing patient selection and registration bias related to the JCOG0802/WJOG4607L trial. It is not a report of a randomized clinical trial with a drug intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study. PMID 41592243 · JNCI Cancer Spectr · 2026-Mar-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. PMID 41493295 · J Am Coll Cardiol · 2026-Mar-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. PMID 41348072 · J Am Coll Cardiol · 2026-Mar-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Significant Incidental Findings in the National Lung Screening Trial and Diagnosis of Extrapulmonary Cancer. PMID 41915394 · JAMA Netw Open · 2026-Mar-02 The record is an original analysis from a large randomized trial (NLST). However, it is not eligible because it is a screening/diagnostic study, not a therapeutic trial. It lacks a drug-containing intervention and a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) for a malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. PMID 41915391 · JAMA Netw Open · 2026-Mar-02 The record reports a randomized clinical trial in oncology with primary time-to-event endpoints (OS, PFS) and a drug-containing intervention. However, the trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata, making it impossible to confirm eligibility under the strict criterion requiring explicit phase evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 41893843 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials. PMID 41885866 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Bayesian Statistics to Reanalyze Data From the STAAMP Trial. PMID 41842893 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory Analysis. PMID 41827741 · Cancers (Basel) · 2026-Mar-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer. PMID 41817524 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial. PMID 41811317 · JAMA Netw Open · 2026-Mar-02 The study is a randomized controlled trial of sivelestat vs placebo in cardiovascular surgery patients, reporting on ARDS incidence and 90-day mortality. While it includes a time-to-event outcome (mortality), it is not an oncology study (ARDS is not a human malignant neoplasm). The trial is not identified as Phase III/IIIb or a definitive oncologic trial. Therefore, it does not meet the core eligibility criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival. PMID 41790469 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Key considerations for safe de-escalation of therapy for POLE mutated endometrial cancer. PMID 41775567 · Int J Gynecol Cancer · 2026-Mar-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Correction: Psychometric evaluation of a pediatric functional constipation symptom diary using randomized phase 3 clinical trial data. PMID 41770459 · J Patient Rep Outcomes · 2026-Mar-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized Trial Links Time of Day to Immunotherapy Success. PMID 41632563 · Cancer Discov · 2026-Mar-02 The record is a news article reporting on a randomized trial, but the abstract lacks explicit details on the trial phase, a specific time-to-event primary/key secondary endpoint, or statistical results like Kaplan-Meier or HR. Therefore, key eligibility criteria cannot be confidently established from the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect Modification by Serum Vitamin A Levels on the Association between Vitamin D and Relapse or Death in Patients with Digestive Tract Cancer. PMID 41524587 · Cancer Epidemiol Biomarkers Prev · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial. PMID 41504649 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer. PMID 41489691 · Clin Cancer Res · 2026-Mar-02 The record is from a randomized oncology trial with drug intervention and time-to-event endpoints. However, the explicit phase (III/IIIb or II/III) is not confirmed in the provided metadata. Per instructions, the phase cannot be inferred.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial. PMID 41427962 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy. PMID 41405563 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer. PMID 41385615 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The 3-Year Results of a 100-Patient Prospective Study of the Safety and Effectiveness of Mia Femtech. PMID 41052824 · Aesthet Surg J · 2026-Mar-02 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and immunogenicity of UB-851 versus Eprex® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial: Erratum. PMID 41859871 · J Chin Med Assoc · 2026-Mar-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -